AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling

Circulation: Heart Failure

Volumn 6, Issue 2, 2013, Pages 310-317

  Fish, Kenneth M ^a   Ladage, Dennis ^a,c   Kawase, Yoshiaki ^a   Karakikes, Ioannis ^a   Jeong, Dongtak ^a   Ly, Hung ^b   Ishikawa, Kiyotake ^a   Hadri, Lahouaria ^a   Tilemann, Lisa ^a   Muller Ehmsen, Jochen ^c   Samulski, R Jude ^d   Kranias, Evangelia G ^e   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Aav9.i 1c; Heart failure; Myocardial infarction; Serc2a

Indexed keywords

ACTIVATING THE INHIBITOR OF PROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; PHOSPHOPROTEIN PHOSPHATASE 1;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 9; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL PIG; FEMALE; GENE OVEREXPRESSION; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; IN VIVO GENE TRANSFER; INTRACORONARY INFUSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOSYNTHESIS; CONVALESCENCE; DISEASE MODEL; ENZYMOLOGY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; HUMAN; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; SWINE; TIME;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; PROTEIN PHOSPHATASE 1; RECOVERY OF FUNCTION; STROKE VOLUME; SWINE; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

MLCS; MLOWN;

EID: 84877284455     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.971325     Document Type: Article

References (29)

1. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 2002;34:951-969.
2. Hasenfuss G, Reinecke H, Studer R, Pieske B, Meyer M, Drexler H, Just H. Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol. 1996;91(suppl 2):17-22.
3. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987;61:70-76.
4. Gwathmey JK, Hajjar RJ. Intracellular calcium related to force development in twitch contraction of mammalian myocardium. Cell Calcium. 1990;11:531-538.
5. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/ SERCA2a regulatome. Circ Res. 2012;110:1646-1660.
6. Florea S, Anjak A, Cai WF, Qian J, Vafiadaki E, Figueria S, Haghighi K, Rubinstein J, Lorenz J, Kranias EG. Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging. Basic Res Cardiol. 2012;107:279.
7. Chen G, Zhou X, Florea S, Qian J, Cai W, Zhang Z, Fan GC, Lorenz J, Hajjar RJ, Kranias EG. Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis. Basic Res Cardiol. 2010;105:573-581.
8. Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, Ly H, Kawase Y, Wagner K, Borow K, Jaski B, London B, Greenberg B, Pauly DF, Patten R, Starling R, Mancini D, Jessup M. Design of a phase trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14:355-367.
9. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase clinical trial. J Card Fail. 2009;15:171-181.
10. Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG. Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol. 2002;22:4124-4135.
11. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med. 2004;10:248-254.
12. Pathak A, del Monte F, Zhao W, Schultz JE, Lorenz JN, Bodi I, Weiser D, Hahn H, Carr AN, Syed F, Mavila N, Jha L, Qian J, Marreez Y, Chen G, McGraw DW, Heist EK, Guerrero JL, DePaoli-Roach AA, Hajjar RJ, Kranias EG. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res. 2005;96:756-766.
13. Rodriguez P, Mitton B, Nicolaou P, Chen G, Kranias EG. Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2007;293:H762-H769.
14. Chen G, Zhou X, Nicolaou P, Rodriguez P, Song G, Mitton B, Pathak A, Zachariah A, Fan GC, Dorn GW II, Kranias EG. A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation. FASEB J. 2008;22:1790-1796.
15. Wittköpper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsöld B, Kirchhof P, Maier LS, Hasenfuss G, Dobrev D, Eschenhagen T, El-Armouche A. Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest. 2010;120:617-626.
16. Rodriguez P, Mitton B, Waggoner JR, Kranias EG. Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem. 2006;281:38599-38608.
17. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6:973-985.
18. Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, Zolotukhin S, Hajjar RJ, Weber T. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther. 2012;20:73-83.
19. Ishikawa K, Ladage D, Tilemann L, Fish K, Kawase Y, Hajjar RJ. Gene transfer for ischemic heart failure in a preclinical model. J Vis Exp. 2011;pii: 2778.
20. El-Armouche A, Wittköpper K, Degenhardt F, Weinberger F, Didié M, Melnychenko I, Grimm M, Peeck M, Zimmermann WH, Unsöld B, Hasenfuss G, Dobrev D, Eschenhagen T. Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res. 2008;80:396-406.
21. Huang B, Wang S, Qin D, Boutjdir M, El-Sherif N. Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases. Circ Res. 1999;85:848-855.
22. Weaver ME, Pantely GA, Bristow JD, Ladley HD. A quantitative study of the anatomy and distribution of coronary arteries in swine in comparison with other animals and man. Cardiovasc Res. 1986;20:907-917.
23. Cademartiri F, La Grutta L, Malagò R, Alberghina F, Meijboom WB, Pugliese F, Maffei E, Palumbo AA, Aldrovandi A, Fusaro M, Brambilla V, Coruzzi P, Midiri M, Mollet NR, Krestin GP. Prevalence of anatomical variants and coronary anomalies in 543 consecutive patients studied with 64-slice CT coronary angiography. Eur Radiol. 2008;18:781-791.
24. Chen J, Petranka J, Yamamura K, London RE, Steenbergen C, Murphy E. Gender differences in sarcoplasmic reticulum calcium loading after isoproterenol. Am J Physiol Heart Circ Physiol. 2003;285:H2657-H2662.
25. Ahmad Z, Green FJ, Subuhi HS, Watanabe AM. Autonomic regulation of type 1 protein phosphatase in cardiac muscle. J Biol Chem. 1989;264:3859-3863.
26. Gupta RC, Neumann J, Watanabe AM, Lesch M, Sabbah HN. Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte. Am J Physiol. 1996;270(4 pt 2):H1159-H1164.
27. Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, Zimmermann N. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol. 1997;29:265-272.
28. El-Armouche A, Rau T, Zolk O, Ditz D, Pamminger T, Zimmermann WH, Jäckel E, Harding SE, Boknik P, Neumann J, Eschenhagen T. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J. 2003;17:437-439.
29. Nicolaou P, Rodriguez P, Ren X, Zhou X, Qian J, Sadayappan S, Mitton B, Pathak A, Robbins J, Hajjar RJ, Jones K, Kranias EG. Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res. 2009;104:1012-1020.